At Biogen, we develop, market and manufacture therapies for people living with serious neurological, autoimmune and hematologic disorders.

from https://www.biogen.com/

Research Grants 21 show all


$23.7M
2013

$32.2M
2015

$22M
2016

$23M
2017

$580.3K
2018

Publications 1,029 show all

  • 21
    Multiple Sclerosis, Relapsing-Remitting/drug therapy
  • 16
    Proteins/chemistry
  • 14
    Protein Engineering/methods
  • 14
    Receptors, Tumor Necrosis Factor/metabolism
  • 13
    Antibodies, Monoclonal/chemistry
  • 12
    Drug Design
  • 12
    Multiple Sclerosis/drug therapy
  • 12
    Tumor Necrosis Factors/metabolism
  • 11
    Antibodies, Monoclonal, Humanized/therapeutic use
  • 11
    Antibodies, Monoclonal/therapeutic use

Patents 5,807show all

  • 2,078
    A61K - Preparations for medical, dental, or toilet purposes
  • 1,911
    C07K - Peptides
  • 446
    C12N - Microorganisms or enzymes
  • 434
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 371
    C07D - Heterocyclic compounds
  • 207
    Y02A - Technologies for adaptation to climate change
  • 126
    A01K - Animal husbandry
  • 126
    C07C - Acyclic or carbocyclic compounds
  • 122
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 93
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture

Clinical Trials 671show all

270N/A189Phase 3123Phase 236Phase 444Other

SEC Filings show all


221
8-K

74
10-Q

22
10-K

Contact Information

Cambridge, MA
United States